Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Open Angle Glaucoma: Treatment01:27

Open Angle Glaucoma: Treatment

1.1K
In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...
1.1K
Glaucoma: Overview01:25

Glaucoma: Overview

1.6K
Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...
1.6K
Angle Closure Glaucoma: Treatment01:28

Angle Closure Glaucoma: Treatment

1.6K
Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...
1.6K
Ophthalmic Drug Delivery Systems01:23

Ophthalmic Drug Delivery Systems

212
Ophthalmic drug delivery faces major limitations due to poor absorption across the corneal membrane. This process is primarily driven by diffusion and is influenced by two main factors: the physicochemical properties of the drug and tear drainage. Most ophthalmic drugs, such as pilocarpine, epinephrine, atropine, and local anesthetics, are weak bases. They are typically formulated at an acidic pH to enhance chemical stability. However, this leads to high ionization, reducing their ability to...
212

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Cytocompatible and photoluminescent nitrogen-doped carbon dots derived from grape seed flour for enhanced fluorescence bioimaging in breast cancer cells.

RSC advances·2026
Same author

Development of Nanoparticle-Hydrogel Drug Delivery System for Sustained Release of Anti-VEGF Peptide in Ocular Neovascularization Treatment.

Macromolecular bioscience·2026
Same author

Current state and potential of polymersomes as ocular drug delivery systems.

Nanoscale·2025
Same author

3D-Printed Functionally Graded PCL-HA Scaffolds with Multi-Scale Porosity.

ACS omega·2025
Same author

Development of pseudotyped VSV-SARS-CoV-2 spike variants for the assessment of neutralizing antibodies.

Bioanalysis·2024
Same author

A Nanogel Formulation of Anti-VEGF Peptide for Ocular Neovascularization Treatment.

ACS applied bio materials·2024

Related Experiment Video

Updated: Mar 28, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.9K

Nanotechnology Applications for Glaucoma.

Sibel Cetinel1, Carlo Montemagno

  • 1From the Chemical and Materials Engineering and Ingenuity Lab, University of Alberta, Edmonton, Alberta, Canada.

Asia-Pacific Journal of Ophthalmology (Philadelphia, Pa.)
|December 24, 2015
PubMed
Summary
This summary is machine-generated.

Nanotechnology offers advanced solutions for glaucoma treatment, improving drug delivery and overcoming limitations of current therapies. These innovations promise to prevent glaucoma-induced blindness through targeted delivery and enhanced bioavailability.

More Related Videos

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres
06:35

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Published on: February 2, 2015

18.0K

Related Experiment Videos

Last Updated: Mar 28, 2026

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice
09:26

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

20.9K
Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents
10:10

Full-Circle Cauterization of Limbal Vascular Plexus for Surgically Induced Glaucoma in Rodents

Published on: February 15, 2022

2.0K
Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres
06:35

Experimental Glaucoma Induced by Ocular Injection of Magnetic Microspheres

Published on: February 2, 2015

18.0K

Area of Science:

  • Ophthalmology
  • Nanomedicine
  • Biotechnology

Background:

  • Glaucoma is a leading cause of blindness globally, with existing treatments causing complications.
  • Current antiglaucoma therapies face challenges in efficacy and side effects.
  • Nanotechnology presents a promising avenue for next-generation glaucoma treatments.

Purpose of the Study:

  • To review recent advances in nanotechnology-based treatment strategies for glaucoma.
  • To highlight how nanotechnology can overcome limitations of current glaucoma therapies.
  • To explore the potential of nanomedicine in preventing glaucoma-induced blindness.

Main Methods:

  • Review of current literature on nanotechnology applications in glaucoma.
  • Analysis of advancements in controlled release, targeted delivery, and bioavailability using nanomaterials.
  • Exploration of nanofabrication systems like microelectromechanical systems (MEMS) for nanodevices.
  • Investigation of tissue regeneration vesicles for novel glaucoma treatment approaches.

Main Results:

  • Nanotechnology enhances antiglaucoma medication efficiency through improved bioavailability and targeted delivery.
  • Nanofabrication systems, including MEMS, address limitations of traditional nanodevices.
  • Tissue regeneration vesicles offer alternative treatment strategies independent of intraocular pressure.
  • Significant progress in nanomedicine is paving the way for advanced glaucoma interventions.

Conclusions:

  • Nanotechnology-based strategies show significant promise for overcoming complications associated with current glaucoma treatments.
  • Advanced nanomedicine and nanofabrication techniques are crucial for developing effective next-generation glaucoma therapies.
  • The integration of nanotechnology offers a future possibility for preventing glaucoma-induced blindness.